Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Epizyme

Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call... 
Tickers EPZM
From Business Wire News Releases
Epizyme Reports Business Progress and First Quarter 2020 Financial Results
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter... 
Tickers EPZM
From Business Wire News Releases
Epizyme Elects Kenneth Bate to Board of Directors
Tickers EPZM
From Business Wire News Releases
Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments
- Potential Therapeutic Candidates Now Identified for All Three GSK Collaboration Targets - 
Tickers EPZM
From PR Newswire
Epizyme to Partner to Develop DOT1L Companion Diagnostic
From PR Newswire
Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
From PR Newswire
Epizyme to Present at Upcoming Conferences in February
From PR Newswire
Epizyme to Present at Upcoming Scientific and Financial Conferences in November
From PR Newswire
Epizyme Forms Strategic Partnership with Industry Leader in Epigenetic Therapies, Celgene Corporation, to Develop Personalized Therapeutics for Genetically-Defined Cancers
Tickers CELG
From Business Wire News Releases
Epizyme to Participate in Upcoming Conferences
From Business Wire News Releases
The Leukemia & Lymphoma Society and Epizyme Announce Achievement of Pre-clinical Milestone in DOT1L Personalized Therapeutic Partnership
From Business Wire News Releases
Epizyme Achieves $4 Million Pre-Clinical Milestone Payment in Eisai Strategic Partnership
From Business Wire News Releases
Epizyme to Present at World Epigenetics Summit and Convergence Forum West
From Business Wire News Releases
Epizyme Achieves $4 Million in Pre-Clinical Milestone Payments in GlaxoSmithKline Alliance to Discover and Develop Novel HMT Therapeutics
From Business Wire News Releases
The Leukemia & Lymphoma Society and Epizyme Partner to Develop Personalized Therapeutic for Genetically-Defined Mixed Lineage Leukemia (MLL) Patients
From Business Wire News Releases
Epizyme Announces Strategic Alliance to Develop Epigenetic Therapeutics
From Business Wire News Releases
Epizyme Awarded $733,000 Grant under Qualified Therapeutic Discovery Project Program
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account